I have been contemplating my personal situation a lot these

New Post Public Reply Private Reply Replies (5) Message Board
docj Buildit #17716
521
I have been contemplating my personal situation a lot these last few months. Too much time on my hands with CV-19 slowing things up a bit.

My birthday is in August. For quite sometime I planned on retiring between then and the end of the year. I have steadily worked towards that goal, eliminating debt etc. Generex was expected to be the investment that put me in a retire "quite comfortably" category. A year ago that looked like a sure thing. Then things started unraveling. We don't need a review of those events. Then CV-19 hit.

As you know I own a good number of shares. I had taken a purchasing break for a bit. Since the 8-k's started coming out steadily and based on my communication with others, I added to my position a bit. Given that I still hope to retire or at least slow down by years end I probably SHOULD stop adding more risk in my portfolio. Having said that, with financing in order for GNBT/NGIO, I consider anything between 50 cents and $1.50 a bargain and would buy whatever amount my investment plan allows for a speculative biotech company.





Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 21

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading

Top 5 Most Recently Viewed Articles

BioXcel Therapeutics Faces Challenges Amidst 52-Week Low

Updated Category News Views 85

BioXcel Therapeutics: Facing the Heat BioXcel Therapeutics Inc. (BTAI) is in the doghouse—its stock just hit a jaw-dropping 52-week low of $0.53. That's an eye-watering drop of over 80% in the last year. Investors are glued to their screens, weighing whether to grab some shares at rock-bottom prices or steer clear as BioXcel grapples with mounting obstacles. This sharp...

Continue Reading
Guidehouse Welcomes Ron White as New Chief Information Officer

Updated Category News Views 315

Guidehouse Appoints Ron White as Chief Information Officer Advancing the firm's AI-led strategy with visionary leadership to drive business transformation and scalable innovation MCLEAN, Va. – Guidehouse, a global AI-led professional services firm, has recently appointed Ron White as its Chief Information Officer (CIO). With over 35 years of expertise in enterprise...

Continue Reading
Natural Ingredients Driving Growth in Cosmetics Market

Updated Category News Views 186

Market Growth Driven by Consumer Demand Recent studies indicate that the chemicals market for cosmetics and toiletries is experiencing significant growth. The market is set to increase from $27.7 billion to an impressive $35 billion by the end of 2029. This momentum speaks volumes about the trends affecting consumer preferences and the investment patterns of leading...

Continue Reading
Securities Investigation Alert for Semler Scientific Investors

Updated Category News Views 118

Understanding the Semler Scientific Investigation The Rosen Law Firm is actively investigating potential securities claims for investors of Semler Scientific, Inc. (NASDAQ: SMLR). This initiative addresses concerns regarding the possibility that the company may have provided significantly misleading information about its business practices to the public. Why You Should Be...

Continue Reading
Exciting Updates from Bitget Wallet: Join Fomo Thursdays

Updated Category News Views 390

Bitget Wallet Introduces Fomo Thursdays Events Bitget Wallet, a prominent non-custodial crypto wallet, is thrilled to announce the launch of its fourth Fomo Thursdays event, brought to life in collaboration with Velo Protocol. This event focuses on broadening participation in the crypto space, featuring a staggering prize pool of 3.47 million VELO tokens and 50,000 slots...

Continue Reading